Clinical Trials
37 trials18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
SPORE-3
University of Iowa
ANAPLAST-NEO
Saint Petersburg State University, Russia
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
PUTNET
Excel Diagnostics and Nuclear Oncology Center
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
NET-PACS
Big Ten Cancer Research Consortium
MIBNET
AC Camargo Cancer Center
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
University of North Carolina, Chapel Hill
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Pasireotide in Hyperinsulinemic Hypoglycemia
Montefiore Medical Center
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Ochsner Health System
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
TELEFIRST
European Organisation for Research and Treatment of Cancer - EORTC
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors
National Taiwan University Hospital
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
TODAY!
Northwestern University
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Academic and Community Cancer Research United
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
CASTOR
Jules Bordet Institute
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
VIBRaNT
University College, London
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Molecular Insight Pharmaceuticals, Inc.
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Dartmouth-Hitchcock Medical Center
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
M.D. Anderson Cancer Center
FACT2
Mateon Therapeutics
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Morphotek
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Boston Medical Center
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)